- Home
- CISS vs SNPX Comparison
CISS vs SNPX Comparison
Compare CISS & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- SNPX
- Stock Information
- Founded
- CISS 2022
- SNPX 2012
- Country
- CISS Greece
- SNPX United States
- Employees
- CISS N/A
- SNPX N/A
- Industry
- CISS Marine Transportation
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- CISS Consumer Discretionary
- SNPX Health Care
- Exchange
- CISS Nasdaq
- SNPX Nasdaq
- Market Cap
- CISS 2.8M
- SNPX 3.1M
- IPO Year
- CISS N/A
- SNPX N/A
- Fundamental
- Price
- CISS $3.56
- SNPX $2.41
- Analyst Decision
- CISS
- SNPX Strong Buy
- Analyst Count
- CISS 0
- SNPX 1
- Target Price
- CISS N/A
- SNPX $14.00
- AVG Volume (30 Days)
- CISS 20.6K
- SNPX 19.8K
- Earning Date
- CISS 05-15-2025
- SNPX 05-15-2025
- Dividend Yield
- CISS N/A
- SNPX N/A
- EPS Growth
- CISS N/A
- SNPX N/A
- EPS
- CISS N/A
- SNPX N/A
- Revenue
- CISS $38,174,754.00
- SNPX N/A
- Revenue This Year
- CISS N/A
- SNPX N/A
- Revenue Next Year
- CISS N/A
- SNPX N/A
- P/E Ratio
- CISS N/A
- SNPX N/A
- Revenue Growth
- CISS N/A
- SNPX N/A
- 52 Week Low
- CISS $2.85
- SNPX $1.84
- 52 Week High
- CISS $25.35
- SNPX $5.05
- Technical
- Relative Strength Index (RSI)
- CISS 43.43
- SNPX 49.39
- Support Level
- CISS $3.55
- SNPX $2.51
- Resistance Level
- CISS $3.83
- SNPX $2.76
- Average True Range (ATR)
- CISS 0.17
- SNPX 0.18
- MACD
- CISS -0.00
- SNPX 0.03
- Stochastic Oscillator
- CISS 1.59
- SNPX 45.10
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.